Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly and Co. (NYSE:LLY), accusing the pharmaceutical giant of bribing medical providers to promote its most profitable drugs, including the widely used GLP-1 medications Mounjaro and Zepbound for diabetes and weight loss.

Paxton's office said the company supplied free nurses to help care for patients who received its drugs, as well as administrative support services that helped providers process insurance claims.

Eli Lilly will raise UK private prices for Mounjaro by up to 170 percent from September 2025, with the highest dose set to cost £330 monthly while NHS prices stay unchanged.

Texas Attorney General Ken Paxton alleges that Eli Lilly bribed Texas medical providers to provide the company's drugs. Eli Lilly denies the claims.

Texas Attorney General Ken Paxton is accusing Eli Lilly and Co. of a kickback scheme to induce medical providers to prescribe the Indianapolis-based company’s drugs including blockbuster GLP-1 medications Mounjaro and Zepbound,